Mechanisms of action and targets for actual and future antiplatelet drugs

Kathleen Freson; Chantal Thys; Christine Wittevrongel; Chris Van Geet

doi:10.2174/138955706777435661

Mechanisms of action and targets for actual and future antiplatelet drugs

Mini Rev Med Chem. 2006 Jun;6(6):719-26. doi: 10.2174/138955706777435661.

Authors

Kathleen Freson¹, Chantal Thys, Christine Wittevrongel, Chris Van Geet

Affiliation

¹ Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium. Kathleen.freson@med.kuleuven.ac.be

PMID: 16787383
DOI: 10.2174/138955706777435661

Abstract

Platelets are key players in arterial thrombosis and have become important targets in the primary and secondary prevention of atherothrombosis. Antiplatelet drugs are primarily directed against platelets and inhibit platelet activation by a number of different mechanisms. They are used for the prevention and treatment of thrombotic processes, especially in the arterial vascular system. Antiplatelet drugs in clinical use and experimental drugs are discussed.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Aspirin / pharmacology
Cyclooxygenase Inhibitors / pharmacology*
Drug Design*
Humans
Platelet Aggregation Inhibitors / chemistry
Platelet Aggregation Inhibitors / pharmacology*
Platelet Membrane Glycoprotein IIb / drug effects*
Purinergic Antagonists*
Pyridines / pharmacology

Substances

Cyclooxygenase Inhibitors
Platelet Aggregation Inhibitors
Platelet Membrane Glycoprotein IIb
Purinergic Antagonists
Pyridines
thienopyridine
Aspirin